InterMune a top 2012 pick, says Brean Murray Brean Murray said negative macro and company specific catalysts created a buying opportunity for InterMune. The firm called it a top pick for 2012 citing valuation, implications for strong German demand of Esbriet, and the orphan drug status of the drug. Shares are Buy rated with a $42 price target.
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.